Sign In

Login

Password

Forgot Password ? Sign Up

Pirazynamid (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Pirazynamid" in Polish language version.

refsWebsite
Global rank Polish rank
51nih.gov
4th place
7th place
5doi.org
2nd place
6th place
1mp.pl
8,738th place
165th place
1who.int
195th place
256th place
1farmapol.pl
low place
low place

doi.org

  • R. Christopher Harmon: Pyrazinamide. W: xPharm: The Comprehensive Pharmacology Reference. Elsevier, 2008. DOI: 10.1016/B978-008055232-3.62492-4.
  • Y. Zhang, M.M. Wade, A. Scorpio, H. Zhang i inni. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. „J Antimicrob Chemother”. 52 (5), s. 790–795, Nov 2003. DOI: 10.1093/jac/dkg446. PMID: 14563891. 
  • O. Zimhony, J.S. Cox, J.T. Welch, C. Vilcheze i inni. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. „Nat Med”. 6 (9), s. 1043–1047, Sep 2000. DOI: 10.1038/79558. PMID: 10973326. 
  • E.J. Forget, D. Menzies. Adverse reactions to first-line antituberculosis drugs. „Expert Opin Drug Saf”. 5 (2), s. 231–249, Mar 2006. DOI: 10.1517/14740338.5.2.231. PMID: 16503745. 
  • P. R, R. Garg, S.K. Verma. Isoniazid- and ethambutol-induced psychosis. „Ann Thorac Med”. 3 (4), s. 149–151, Oct 2008. DOI: 10.4103/1817-1737.43083. PMID: 19561898. 

farmapol.pl

mp.pl

indeks.mp.pl

  • Indeks leków Medycyny Praktycznej 2009. Kraków: Wydawnictwo Medycyna Praktyczna, 2009. ISBN 978-83-7430-221-0.; Pyrazinamid Farmapol [online], Medycyna praktyczna dla lekarzy [dostęp 2018-11-18].

nih.gov

ncbi.nlm.nih.gov

  • Y. Zhang, D. Mitchison. The curious characteristics of pyrazinamide: a review. „Int J Tuberc Lung Dis”. 7 (1), s. 6–21, Jan 2003. PMID: 12701830. 
  • D. McKenzie, L. Malone. The effect of nicotinic acid amide on experimental tuberculosis of white mice. „J Lab Clin Med”. 33 (10), s. 1249–1253, Oct 1948. PMID: 18886322. 
  • L. Malone, A. Schurr, H. Lindh, D. McKenzie i inni. The effect of pyrazinamide (aldinamide) on experimental tuberculosis in mice. „Am Rev Tuberc”. 65 (5), s. 511–518, May 1952. PMID: 14924173. 
  • M. Solotorovsky, F.J. Gregory, E.J. Ironson, E.J. Bugie i inni. Pyrazinoic acid amide; an agent active against experimental murine tuberculosis. „Proc Soc Exp Biol Med”. 79 (4), s. 563–565, Apr 1952. PMID: 14920496. 
  • H.H. Fox. The chemical approach to the control of tuberculosis. „Science”. 116 (3006), s. 129–134, Aug 1952. PMID: 14950210. 
  • N. Rist, F. Grumbach, D. Libermann. Experiments on the antituberculous activity of alpha-ethylthioisonicotinamide. „Am Rev Tuberc”. 79 (1), s. 1–5, Jan 1959. PMID: 13606329. 
  • W. Steenken, E. Wolinsky. The antituberculous activity of pyrazinamide in vitro and in the guinea pig. „Am Rev Tuberc”. 70 (2), s. 367–369, Aug 1954. PMID: 13180876. 
  • R.L. Yeager, W.G. Munroe, F.I. Dessau. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. „Trans Annu Meet Natl Tuberc Assoc”. 48, s. 178–201, 1952. PMID: 13038888. 
  • W. McDermott, R. Tompsett. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. „Am Rev Tuberc”. 70 (4), s. 748–754, Oct 1954. PMID: 13197751. 
  • K. Konno, F.M. Feldmann, W. McDermott. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. „Am Rev Respir Dis”. 95 (3), s. 461–469, Mar 1967. PMID: 4225184. 
  • Y. Zhang, M.M. Wade, A. Scorpio, H. Zhang i inni. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. „J Antimicrob Chemother”. 52 (5), s. 790–795, Nov 2003. DOI: 10.1093/jac/dkg446. PMID: 14563891. 
  • Y. Zhang, A. Scorpio, H. Nikaido, Z. Sun. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. „J Bacteriol”. 181 (7), s. 2044–2049, Apr 1999. PMID: 10094680. 
  • Y. Zhang, S. Permar, Z. Sun. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. „J Med Microbiol”. 51 (1), s. 42–49, Jan 2002. PMID: 11800471. 
  • I. Toida. Effect of pyrazinamide on nicotinamide adenine dinucleotide glycohydrolase of tuberculous host. „Am Rev Respir Dis”. 107 (4), s. 648–655, Apr 1973. PMID: 4348945. 
  • Structure Summary, 3GBC, 80790. [dostęp 2010-04-23].
  • O. Zimhony, J.S. Cox, J.T. Welch, C. Vilcheze i inni. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. „Nat Med”. 6 (9), s. 1043–1047, Sep 2000. DOI: 10.1038/79558. PMID: 10973326. 
  • H.I. Boshoff, V. Mizrahi. Purification, gene cloning, targeted knockout, overexpression, and biochemical characterization of the major pyrazinamidase from Mycobacterium smegmatis. „J Bacteriol”. 180 (22), s. 5809–5814, Nov 1998. PMID: 9811635. 
  • H.I. Boshoff, V. Mizrahi. Expression of Mycobacterium smegmatis pyrazinamidase in Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides. „J Bacteriol”. 182 (19), s. 5479–5485, Oct 2000. PMID: 10986252. 
  • K. Ichida, M. Hosoyamada, I. Hisatome, A. Enomoto i inni. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. „J Am Soc Nephrol”. 15 (1), s. 164–173, Jan 2004. PMID: 14694169. 
  • K. Fuursted. Comparison of growth and susceptibility testing of pyrazinamide in different Bactec media using strains of the M. tuberculosis complex. „APMIS”. 101 (2), s. 154–159, Feb 1993. PMID: 8489766. 
  • R. Bonicke. Present status of methods for the routine differentiation of various species of Mycobacterium. „Ann Soc Belg Med Trop (1920)”. 42, s. 403–439, Aug 1962. PMID: 13968795. 
  • K.D. Stottmeier, R.E. Beam, G.P. Kubica. Determination of drug susceptibility of mycobacteria to pyrazinamide in 7H10 agar. „Am Rev Respir Dis”. 96 (5), s. 1072–1075, Nov 1967. PMID: 4964643. 
  • L. Heifets. Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. „J Med Microbiol”. 51 (1), s. 11–12, Jan 2002. PMID: 11800467. 
  • Z. Sun, A. Scorpio, Y. Zhang. The pncA gene from naturally pyrazinamide-resistant Mycobacterium avium encodes pyrazinamidase and confers pyrazinamide susceptibility to resistant M. tuberculosis complex organisms. „Microbiology”. 143 (Pt 10), s. 3367–3373, Oct 1997. PMID: 9353938. 
  • L.B. Heifets, P.J. Lindholm-Levy. Is pyrazinamide bactericidal against Mycobacterium tuberculosis?. „Am Rev Respir Dis”. 141 (1), s. 250–252, Jan 1990. PMID: 2105072. 
  • J.M. Dickinson, D.A. Mitchison. Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis. „Tubercle”. 51 (4), s. 389–396, Dec 1970. PMID: 4992755. 
  • N. Mor, A. Esfandiari. Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. „Antimicrob Agents Chemother”. 41 (9), s. 2035–2036, Sep 1997. PMID: 9303411. 
  • A. Scorpio, P. Lindholm-Levy, L. Heifets, R. Gilman i inni. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. „Antimicrob Agents Chemother”. 41 (3), s. 540–543, Mar 1997. PMID: 9055989. 
  • A. Scorpio, Y. Zhang. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. „Nat Med”. 2 (6), s. 662–667, Jun 1996. PMID: 8640557. 
  • G.L. Treece, C.R. Magnussen, J.R. Patterson, D.P. Tschudy. Exacerbation of porphyria during treatment of pulmonary tuberculosis. „Am Rev Respir Dis”. 113 (2), s. 233–237, Feb 1976. PMID: 1247237. 
  • M. le Bourgeois, J. de Blic, J. Paupe, P. Scheinmann. Good tolerance of pyrazinamide in children with pulmonary tuberculosis. „Arch Dis Child”. 64 (1), s. 177–178, Jan 1989. PMID: 2923471. 
  • T.F. Yü, J. Perel, L. Berger, J. Roboz i inni. The effect of the interaction of pyrazinamide and probenecid on urinary uric acid excretion in man. „Am J Med”. 63 (5), s. 723–728, Nov 1977. PMID: 930947. 
  • C. Lacroix, C. Guyonnaud, M. Chaou, H. Duwoos i inni. Interaction between allopurinol and pyrazinamide. „Eur Respir J”. 1 (9), s. 807–811, Oct 1988. PMID: 3229478. 
  • L.A. Jiménez del Cerro, F. Rivera Hernández. Effect of pyrazinamide on ciclosporin levels. „Nephron”. 62 (1), s. 113, 1992. PMID: 1436277. 
  • C.A. Peloquin, A.T. Nitta, W.J. Burman, K.F. Brudney i inni. Low antituberculosis drug concentrations in patients with AIDS. „Ann Pharmacother”. 30 (9), s. 919–925, Sep 1996. PMID: 8876848. 
  • T. Papastavros, L.R. Dolovich, A. Holbrook, L. Whitehead i inni. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. „CMAJ”. 167 (2), s. 131–136, Jul 2002. PMID: 12160118. 
  • H.X. Lou, M.A. Shullo, T.P. McKaveney. Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population. „Pharmacotherapy”. 22 (6), s. 701–704, Jun 2002. PMID: 12066961. 
  • D.J. Girling. The role of pyrazinamide in primary chemotherapy for pulmonary tuberculosis. „Tubercle”. 65 (1), s. 1–4, Mar 1984. PMID: 6428014. 
  • D.L. Combs, R.J. O’Brien, L.J. Geiter. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. „Ann Intern Med”. 112 (6), s. 397–406, Mar 1990. PMID: 2155569. 
  • G.A. Ellard, R.M. Haslam. Observations on the reduction of the renal elimination of urate in man caused by the administration of pyrazinamide. „Tubercle”. 57 (2), s. 97–103, Jun 1976. PMID: 960228. 
  • T.P. Rao, J.K. Schmitt. Gout secondary to pyrazinamide and ethambutol. „Va Med Q”. 123 (4), s. 271, 1996. PMID: 8909152. 
  • E.J. Forget, D. Menzies. Adverse reactions to first-line antituberculosis drugs. „Expert Opin Drug Saf”. 5 (2), s. 231–249, Mar 2006. DOI: 10.1517/14740338.5.2.231. PMID: 16503745. 
  • R.A. Sharp, J.G. Lowe, R.N. Johnston. Anti-tuberculous drugs and sideroblastic anaemia. „Br J Clin Pract”. 44 (12), s. 706–707, Dec 1990. PMID: 2102203. 
  • R.K. MacCurdy, E.R. Simon. Thrombocytopenia and sideroblastic anemia with pyrazinoic acid amide (pyrazinamide) therapy. „Chest”. 57 (4), s. 378–381, Apr 1970. PMID: 5434719. 
  • D. Perdu, F. Lavaud, A. Prévost, F. Deschamps i inni. Erythema multiforme due to pyrazinamide. „Allergy”. 51 (5), s. 340–342, May 1996. PMID: 8836340. 
  • J. Jorgensen. Pellagra probably due to pyrazinamide: development during combined chemotherapy of tuberculosis. „Int J Dermatol”. 22 (1). s. 44–45. PMID: 6832880. 
  • J. Goldberg, F. Moreno, J. Barbara. Acute hypertension as an adverse effect of pyrazinamide. „JAMA”. 277 (17), s. 1356, May 1997. PMID: 9134939. 
  • P. R, R. Garg, S.K. Verma. Isoniazid- and ethambutol-induced psychosis. „Ann Thorac Med”. 3 (4), s. 149–151, Oct 2008. DOI: 10.4103/1817-1737.43083. PMID: 19561898. 
  • API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. „J Assoc Physicians India”. 54, s. 219–234, Mar 2006. PMID: 16800350. 
  • G.H. Malik, A.S. Al-Harbi, S. Al-Mohaya, H. Al-Khawajah i inni. Eleven years of experience with dialysis associated tuberculosis. „Clin Nephrol”. 58 (5), s. 356–362, Nov 2002. PMID: 12425486. 
  • C.M. Nolan, R.E. Sandblom, K.E. Thummel, J.T. Slattery i inni. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. „Chest”. 105 (2), s. 408–411, Feb 1994. PMID: 7508362. 

who.int

whqlibdoc.who.int